Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: LarryS who wrote (7242)	9/14/1998 10:30:00 AM
From: Slugger	Respond to of 17367

Here's a link to the XOMA press release: nt.excite.com If this update has to do with the September review then, most likely, we didn't get a stoppage for approval.

To: LarryS who wrote (7242)	9/14/1998 11:57:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

From St Mary's hospital in London (Saul Faust) research on Kawasaki disease which may be caused by a superantigen. Check out the annual report or info area for comments on meningococcal sepsis. (old 94/95) sm.ic.ac.uk sm.ic.ac.uk

To: LarryS who wrote (7242)	9/18/1998 11:57:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

Larry, here is a site that I just could not throw away. Don't see how it is of much real use but it has the appearance of providing a ton of in depth information. ascp.com BTW due to Rosh Hashana the DSMB may not get their letter of recommendation to XOMA until Wed. Even if a halt was recommended it seems XOMA would discuss the recommendation with the F.D.A. before actually halting the trial. This is my understanding of what I think I have heard. What I do not understand is if the DSMB recommendation is almost entirely a statistical report why the recommendation this time seems to be taking longer than one's impression of how long previous recommendations took. I would think it would be easy to quickly recommend that the trials proceed and even easier to say stop when a drug was generating safety concerns. This does not mean I conclude the trial will be stopped early for exceptional efficiency but only that I do not see the delay as a negative.